Moolec Science S.A.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alejandro Antalich
- Full Time Employees
- 52
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 17 Boulevarrd F.W. Raiffeisen, Luxembourg Luxembourg 2411
- IPO Date
- Mar 2, 2021
- CIK
- 0001937737
- Website
- moolecscience.com
- Similar Companies
- Business
- Moolec Science S.A. (NASDAQ: MLEC) is a science-based food ingredient company that develops real animal proteins and nutritional oils in plants through molecular farming technology; it produces animal proteins engineered into plant genomes to enhance functionality in taste, texture, and nutrition for applications in food, pet food, animal feed, and dietary supplements. Core products include VALORASOY™, a texturized soy protein mimicking meat texture sold to distributors and food producers worldwide from a 10,000-ton-per-year facility in Argentina; pipeline offerings such as Piggy Sooy™ (plant-based pork protein), GLASO™ (safflower oil rich in gamma-linolenic acid), SPC2 (plant-based chymosin), and YEEA1 (yeast biomass extract); and integrated solutions like Mycofood™ under the Eternal® brand for alternative proteins. The company operates across North and South America, Europe, the United States, United Kingdom, Netherlands, and Cayman Islands, with revenues primarily from Argentina-based operations; founded in 2020 with headquarters in Luxembourg at 17 Boulevard F.W. Raiffeisen. In a major strategic expansion completed in June 2025, Moolec closed a transformational business combination with Bioceres Group, Nutrecon, and Gentle Technologies Corp., issuing up to 87 million shares and 5 million warrants to integrate biological agriculture technologies including Rizobacter®, ProFarm®, and HB4® drought-tolerant seeds; advanced R&D, CDMO, and regulatory services via Agrality® and Synbio Powerlabs®; and emerging biomaterials and autonomous farming equipment. This all-stock transaction, announced in April 2025 and backed by 70% of shareholders, combines over 800 patents, 550 product registrations, and more than $500 million in annual sales across 50 countries, enabling portfolio diversification, operational synergies, and growth in regenerative agriculture, food-tech, and bioeconomy sectors. The deal positions Moolec to accelerate molecular farming commercialization while expanding upstream capabilities in climate-resilient crops and downstream manufacturing.
Moolec Science Successfully Completes 2026 GLASO Commercial Planting Campaign in the United States
Moolec Science SA Regains Compliance with All Nasdaq Capital Market Continued Listing Requirements Within Panel Remediation Period
Moolec Science Confirms Completion of First Phase of GLASO Industrialization Following Record 2025 Campaign; Advances 2026 Sowing and Expands Into Energy Applications
Moolec Science Announces Breakthrough in Molecular Farming With Successful Expression of Bovine Myoglobin in Pea Seeds
Moolec Science (MLEC) Projected to Post Earnings on Tuesday
Head-To-Head Review: Bioceres Crop Solutions (NASDAQ:BIOX) and Moolec Science (NASDAQ:MLEC)
Analyzing Moolec Science (NASDAQ:MLEC) & Dole (NYSE:DOLE)
Moolec Science (MLEC) Stock Explodes 90% After GLA Update
Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing
Moolec Science Granted Continued Listing on Nasdaq Subject to Hearings Panel Conditions
Moolec Science S.A. Receives Nasdaq Staff Memo Supporting Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
Moolec Science S.A. Receives Nasdaq Panel Exception Through June 29, 2026 to Regain Compliance with Stockholders' Equity Requirement
Moolec Science Announces Effectiveness of Share Consolidation
Moolec Receives Staff Determination Letter and Provides Update on Nasdaq Listing Compliance Status
Moolec Science SA Announces the Implementation of a Share Consolidation of Its Ordinary Shares, Par Value U.S.$0.10 Per Share (the "Shares")
Moolec Science Scales GLASO U.S. Platform With Record 2025 Campaign and Expansion Into Nutrition & Supplements Market
Reviewing Moolec Science (NASDAQ:MLEC) and CHS (NASDAQ:CHSCP)
Pyxus International (OTCMKTS:PYYX) and Moolec Science (NASDAQ:MLEC) Head to Head Comparison
Moolec Receives Nasdaq Determination Letter
Financial Review: Scheid Vineyards (OTCMKTS:SVIN) vs. Moolec Science (NASDAQ:MLEC)